Moreover, considering the frequent alterations of THSD7B, SYNE2, GRM3, and FLNC in lung squamous cell carcinoma and lung adenocarcinoma (Figure S6), we investigated the applicability of ITS to NSCLC patients treated with ICIs. The gene discussed is GRM3; the disease is squamous cell lung carcinoma.